YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

NCT07461454 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: YL202
DRUG: Eribulin
DRUG: Capecitabine
DRUG: Gemcitabine
DRUG: Vinorelbine
DRUG: Sacituzumab govitecan

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.